Oral Antidiabetic Utilization and Various Factors as an Indicator for HbA1c Control Among Patients with Type 2 Diabetes

Iche A. Liberty  
Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia, iche.aliberty@gmail.com

Eddy Roflin  
Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia

Muhammad Aziz  
Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia

Pariyana Pariyana  
Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia

Suryadi Tjekyan  
Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia

Follow this and additional works at: https://scholarhub.ui.ac.id/mjhr

Recommended Citation
Liberty IA, Roflin E, Aziz M, Pariyana P, Tjekyan S. Oral Antidiabetic Utilization and Various Factors as an Indicator for HbA1c Control Among Patients with Type 2 Diabetes. Makara J Health Res. 2018;22.
Oral Antidiabetic Utilization and Various Factors as an Indicator for HbA1c Control Among Patients with Type 2 Diabetes

Iche A Liberty*, Eddy Roflin, Muhammad Aziz, Pariyana, Suryadi Tjekyan

Department of Public Health and Community Medicine, Medical Faculty, Sriwijaya University, Palembang, 30114, Indonesia

*E-mail: iche.aliberty@gmail.com

Abstract

Background: Diabetes mellitus requires aggressive long-term therapy to decrease morbidity and mortality. Non-adherence to oral antidiabetic therapy represents a barrier to treatment that could lead to the deterioration of patient health. This study aimed to develop an indicator for predicting glycemic control among patients with type 2 diabetes.

Methods: This unmatched case–control study recruited 110 patients from the Primary Health Care center in Palembang City. The chi-square test was used for certain variables, and multivariate analysis was performed using unconditional logistic regression to assess the effects of different variables after considering certain sociodemographic and economic characteristics as potential confounding variables. Results: The results revealed no statistically significant association of sociodemographic and economic variables (sex, age, education, and employment) with glycemic control. Family history of diabetes, duration of diabetes, body mass index, adherence, monitoring, therapy, and comorbidity were associated with glycemic control.

Conclusions: Continuous education of primary care physicians is one way of improving skills for managing hyperglycemic patients. However, the challenge in treating patients with type 2 diabetes is to shift the main criterion from a disease-oriented to patient-centered approach in the context of patients' circumstances. Additionally, our developed indicator can be used as a screening test for assessing glycemic.

Keywords: antidiabetic, HbA1c, indicator, utilization

Introduction

Diabetes mellitus (DM) is associated with diseases such as heart disease, stroke, and kidney failure. Diabetes requires aggressive long-term therapy to decrease the morbidity and mortality resulting from complications. Glycemic control in diabetes is a “biomedical goal.” However, comprehensive management must encompass both biomedical and biopsychosocial aspects. Several studies have identified patient adherence to treatment as an important biopsychosocial aspect.1,2 Non-adherence is a barrier to successful treatment that may worsen the health status of the patient, leading to errors in future treatments.1 Non-adherence or non-compliance is the main cause of poor glycemic control among patients with type 2 diabetes. The prevalence of non-adherence is high among patients with diabetes, consequently increasing treatment costs.1 As an example, non-adherence is believed to increase healthcare costs in the US by $100 billion per year.2

A study in Nigeria identified financial constraints as the most common cause of non-adherence cited by patients with type 2 diabetes.4 Meanwhile, a separate study surveyed older adults in the Netherlands with type 2 DM who demonstrated greater adherence with social support and routine medication-taking behaviors.5 Unfortunately, these determinants have differed in various studies. Several studies have examined medication adherence in patients with diabetes around the world.3 However, few studies have been conducted in Indonesia. Additionally, few studies have examined the association of various factors with treatment adherence using indicators of outcome such as hemoglobin A1c (HbA1c). For these reasons, we sought to develop an indicator for predicting glycemic control among patients with type 2 diabetes with knowing oral antidiabetic drug utilization and the various factors that associated. These findings may clarify the association of poor glycemic control with comorbidity among patients and provide insights into the successful management of this chronic illness in the future.

Methods

This research was conducted from August 2017 to November 2017, and 110 patients (55 cases and 55...
controls) were randomly selected from the Primary Health Care center in Palembang City. Patients were informed that personal information would be protected. The study was approved by Health Research Review Committee of Mohammad Hoesin Central General Hospital and Faculty of Medicine Sriwijaya University with Ethical Approval Certificate Number: No.61/kepkrsmhfkunsri.

The inclusion criteria for the case group were a diagnosis of type 2 DM by a general practitioner or internist, willingness to participate in the study, provision of informed consent, HbA1c ≥7% or ≥53 mm/mol based on laboratory data for at least 3 months, and oral antidiabetic drug use for at least 3 months. Meanwhile, patients in the control group had HbA1c levels of less than 7% or 53 mm/mol. Pregnant female patients, patients using insulin for the treatment of DM, and non-domiciled patients in Palembang City were excluded from the study. Sociodemographic, disease, and comorbidity data were measured using standard methods. HbA1c levels were measured using a laboratory standard. Body mass index (BMI) is calculated as the weight (kg) divided by height (m). Standing height is measured using a stadiometer bar, without shoes, with shoulders in a relaxed position and arms hanging freely, and recorded to the nearest 0.1 cm. Body weight is measured when wearing light clothing with- out shoes on a digital electronic weighing scale (TD 150, range 4-150 kg). Body mass index (BMI) is then calculated as the weight (kg) divided by height (m2). Adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). For each item of the MMAS-8, a score of 1 was given for a positive answer (i.e., yes), whereas a score of 0 was given for a negative answer (i.e., no). The final score is tabulated as the sum of the scores of the eight items, with scores ≥3 indicating non-adherence.3,6 The eight items of MMAS-8 are presented in Table 1, with alternate answer of Never; Once in a while; Sometimes; Usually; All the time.

All variables (even if originally continuous such as Age, Body Mass Index and time since diagnosis with diabetes were categorized in dichotomous variables - Age (<45 years/≥45 years), Body Mass Index (obese/normal), time since diagnosis (<3 years/≥3 years), monitoring (routine/not routine), drug standard therapy (monotherapy/combination), comorbidity (moderate/severe), education (primary/middle school/high school), employment (formal/informal/unemployed), and family history (yes/no).

**Data analysis.** Data analysis was conducted using STATA ver. 15.0 (College Station, Texas 77845 USA). The significance level was set as two-sided p value < 0.05. The chi-square test and contingency coefficient test were used for certain variables. Multi-variate analysis was performed using unconditional logistic regression to assess the effects of different variables after considering certain sociodemographic and economic characteristics as potential confounding variables. Data are presented as odds ratio with 95% confidence intervals to illustrate the association between variables and outcome, i.e., glycemic control.

**Results**

The study found that there were significant association of family history of diabetes, body mass index, time since diagnosis of diabetes, blood glucose monitoring, standard therapy type, adherence, and comorbidity with oral antidiabetic drug utilization (p < 0.05) (Table 2).

After conducting multivariate analysis with logistic regression (Table 3), the following formula was devised to predict the risk of treatment non-adherence:

\[
\text{Logit Glycemic Control} = -0.708 + 1.20 (\text{family history}) + 1.74 (\text{BMI}) - 1.89 (\text{time since diagnosis}) - 1.50 (\text{monitoring}) - 1.38 (\text{drug standard therapy}) - 1.28 (\text{adherence}) + 2.16 (\text{comorbidity}).
\]

**Table 1. The 8-item morisky medication adherence scale**

| Item | Question |
|------|----------|
| 1    | Do you sometimes forget to take your medicine? |
| 2    | People sometimes miss taking their medicines for reasons other than forgetting. Thinking over the past 2 weeks, were there any days when you did not take your medicine? |
| 3    | Have you ever cut back or stopped taking your medicine without telling your doctor because you felt worse when you took it? |
| 4    | When you travel or leave home, do you sometimes forget to bring along your medicine? |
| 5    | Did you take all your medicines yesterday? |
| 6    | When you feel like your symptoms are under control, do you sometimes stop taking your medicines? |
| 7    | Do you ever feel hassled about sticking to your treatment plan? |
| 8    | How often do you have difficulty remembering to take all your medicine? |
### Table 2. Association of various factors with glycemic control in patients with type 2 diabetes mellitus (DM)

| Variables                        | Uncontrolled DM (Case) | Controlled DM (Control) | p    |
|----------------------------------|------------------------|-------------------------|------|
|                                  | Number (n = 55)        | Percent (%)             |      |
| Sex                              | Uncontrolled DM (Case) | Controlled DM (Control) |      |
| Sex                              | 24                     | 47.1                    | 27   | 52.9 | 0.702 |
| Male                             | 24                     | 47.1                    | 27   | 52.9 | 0.702 |
| Female                           | 31                     | 52.5                    | 28   | 47.5 |      |
| Age                              | 8                      | 72.7                    | 3    | 27.3 | 0.204 |
| <45 years                        | 8                      | 72.7                    | 3    | 27.3 | 0.204 |
| ≥45 years                        | 47                     | 47.5                    | 52   | 52.5 |      |
| Education                        |                        |                        |      |      |      |
| Family history of diabetes       | 44                     | 57.1                    | 33   | 42.9 | 0.037*|
| Yes                              | 44                     | 57.1                    | 33   | 42.9 | 0.037*|
| No                               | 11                     | 33.3                    | 22   | 66.7 |      |
| Body mass index                  |                        |                        |      |      |      |
| Obese                            | 17                     | 68.0                    | 8    | 32.0 | 0.041*|
| Normal                           | 38                     | 44.7                    | 47   | 55.3 |      |
| Time Since Diagnosis of Diabetes |                        |                        |      |      |      |
| <3 years                         | 28                     | 60.9                    | 18   | 39.1 | 0.034*|
| ≥3 years                         | 27                     | 42.2                    | 37   | 57.8 |      |
| Monitoring                       |                        |                        |      |      |      |
| Routine                          | 42                     | 60.0                    | 28   | 40.0 | 0.010*|
| Not routine                      | 13                     | 32.5                    | 27   | 67.5 |      |
| Standard drug therapy            |                        |                        |      |      |      |
| Monotherapy                      | 23                     | 39.7                    | 35   | 60.3 | 0.036*|
| Combination                      | 32                     | 61.5                    | 20   | 38.5 |      |
| Adherence                        |                        |                        |      |      |      |
| Good                             | 29                     | 63.0                    | 17   | 37.0 | 0.033*|
| Poor                             | 26                     | 40.6                    | 38   | 59.4 |      |
| Comorbidity                      |                        |                        |      |      |      |
| Moderate                         | 18                     | 36.0                    | 32   | 64.0 | 0.013*|
| Severe                           | 37                     | 61.7                    | 23   | 38.3 |      |

*Chi-square test, p < 0.05.

### Table 3. Multivariate analysis of factors associated with glycemic control

| Variables                  | B   | Sig.   | Exp(B) | 95% CI          |
|----------------------------|-----|--------|--------|-----------------|
|                            |     |        |        | Lower | Upper |
| Family history             | 1.203| 0.030  | 3.33   | 1.13  | 9.85  |
| Body mass index            | 1.743| 0.009  | 5.71   | 1.55  | 21.10 |
| Duration of diabetes       | -1.888| 0.002  | 0.15   | 0.05  | 0.49  |
| Standard drug Therapy      | 1.376| 0.018  | 3.96   | 1.27  | 12.40 |
| Adherence                  | -1.282| 0.018  | 0.28   | 0.09  | 0.80  |
| Monitoring                 | -1.503| 0.010  | 0.22   | 0.07  | 0.69  |
| Comorbidity                | 2.156| 0.000  | 8.63   | 2.67  | 27.94 |
| Constant                   | -0.708| 0.308  | 0.49   |       |       |

*Reference: 1= Yes; 0 = No
Discussion

The analysis found no associations of age, gender, education, and employment with oral antidiabetic drug utilization, in line with the findings of the Hill–Briggs study, which observed no correlation between gender and level of adherence to diabetes medications among African-Americans. However, these findings differ from those of previous study, who found that patients with more strenuous work schedules had higher inclinations toward non-compliance. Adherence is a key issue, especially for chronic illnesses such as DM. Non-adherence results in elevation of blood sugar levels and subsequent microvascular and macrovascular complications. In the study, family history of diabetes was examined for each patient’s mother and father. An association between family history and HbA1c levels was indicated. This association was largely explained for the association of parental history of diabetes with a longer duration of diabetes.

In this observational study, we found an association between adherence and glycemic control (HbA1c). The results indicated that early adherence has a profound effect on glycemic control. Better adherence was associated with better responses to and the durability of metformin monotherapy as well as metformin and sulfonylurea combination therapy. Because medication adherence represents a complex series of patient behaviors rather than a single construct, the cumulative glycemic burden experienced by patients with diabetes over time could be substantially lowered by adherence behaviors established early in the course of diabetes. The potential reasons for poor glycemic control include high carbohydrate food consumption, a lack of physical activity, and a lack of knowledge about diabetes and its treatment. In Palembang City, the main food staple in the community is pempek, which consists of a mixture of fish and sago. Consumption of this local specific food is presumed to have resulted in high carbohydrate consumption among patients with diabetes in this study.

The finding of an association of time since diagnosis diabetes with glycemic control was in line with the previous study, who identified a correlation between the duration of DM and glycemic control (HbA1c). In their study, each 1-year increase in the duration of DM was associated with a 5% reduction in the likelihood of achieving glycemic control. Therefore, with disease progression, most patients require an increase in pharmacotherapy to maintain glycemic control. In general, patients with type 2 diabetes start pharmacotherapy with metformin, but treatment with more than one oral antidiabetic drug might be needed to maintain glycemic control. A number of studies have indicated that adherence decreases as the number of drugs increases.

Another important variable that can predict glycemic control among patients with type 2 diabetes is comorbidity. In this research, we found that comorbidity had a highly significant association with glycemic control. The time since diagnosis of diabetes has been as an independent risk factor for comorbidity, as it is highly correlated with the number of complications and severity disease. This study had several limitations. First, this was a retrospective study with a small sample size, and the risk of recall bias cannot be dismissed. Second, patients using insulin were excluded. Third, other variables with potential associations with glycemic control were not measured, including regimen complexity, medication beliefs, and other human and economic factors. Future research should focus on the interplay between adherence to insulin and other anti-diabetic therapies with follow-up observation.

Conclusions

Our findings identified several factors associated with uncontrolled diabetes, including family history, body mass index, time since diagnosis of diabetes, blood glucose monitoring, standard therapy type, adherence level, and comorbidity. Continuous education of primary care physicians is one way of improving skills for managing hyperglycemic patients. However, the challenge in treating patients with type 2 diabetes in the face of increasing comorbidity is to shift the main criterion from a disease-oriented to patient-centered approach in the context of patients’ circumstances. Additionally, our developed indicator can be used as a screening test for assessing glycemic control in an effort to reduce the cost of health care and medical complications associated with DM.

Acknowledgments

We would like to thank to Lembaga Penelitian dan Pengabdian Masyarakat, Sriwijaya University for financing this research and publishing this article. This work is supported by the Medical Faculty of Sriwijaya University, Government of South Sumatera Province, Health Department of Palembang. We would additionally like to thank the Participating Community Health Centers staff for their efforts and acknowledge the assistance of our students Reinika and Hana Andriana in conducting this study.

Funding

This this research was funded by Lembaga Penelitian dan Pengabdian Masyarakat, Sriwijaya University.

Conflict of Interest Statement

The authors declared no conflict of interest.

References

1. Albuquerque C, Correia C, Ferreira M. Adherence to the therapeutic regime in person with type 2 diabetes. Procedia Soc Behav Sci. 2015;171:350-8.
2. Shams ME, Barakat EA. Measuring the rate of therapeutic adherence among outpatients with T2DM in Egypt. Saudi Pharm J. 2010;18:225-32.
3. Mohd MM, Phung H, Sun J, Morisky DE. The predictors to medication adherence among adults with diabetes in the United Arab Emirates. J Diabetes Metab Disord. 2016;15:30.
4. Pascal IG, Ofoedu JN, Uchenna NP, Nkwa AA, Uchamma GU. Blood glucose control and medication adherence among adult type 2 diabetic nigerians attending a primary care clinic in under-resourced environment of Eastern Nigeria. North Am J Med Sci. 2012;4:7.
5. Borgsteede SD, Westerman MJ, Kok IL, Meese JC, De Vries TPGM, Hugtenburg JG. Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. Int J Clin Pharm. 2011;33:779-87.
6. Hill-Briggs F, Gary TL, Bone LR, Hill MN, Levine DM, Brancati FL. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol. 2005;24:349-57.
7. Fai EK, Anderson C, Ferreros V. Role of attitudes and intentions in predicting adherence to oral diabetes medications. Endocr Connect. 2017; 6:63-70
8. Jimmy B, Jose J, Al-Hinai ZA, Wadair IK, Al-Amri GH. Adherence to Medications among Type 2 Diabetes Mellitus Patients in Three Districts of Al Dakhiliyah Governorate, Oman. Sultan Qaboos University Med J. 2014:14:231-5.
9. Delamater AM. Improving patient adherence. Clin Diabet. 2006;24:71-7.
10. Gong L, Kao WH, Brancati FL, Bates-Turner M, Gary TL. Association between parental history of type 2 diabetes and glycemic control in urban African Americans. Diabetes Care. 2008;31.
11. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin. 2010;26:2127-35.
12. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501-6.
13. Steiner JF. Rethinking adherence. Ann Intern Med. 2012;157:580-5.
14. Nichols GA, Rosales AG, Kimes TM, Tuncel K, Kurtyka K, Mavros P. The change in HbA1c associated with initial adherence and subsequent change in adherence among diabetes patients newly initiating metformin therapy. J Diabetes Res. 2016;2016:9687815.
15. Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with poor glycemic control among patients with type 2 diabetes mellitus. J Diabetes Invest. 2014;5:563-9.
16. Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, et al. Use of anti-diabetic drugs and glycemic control in type 2 diabetes. The Hong Kong Diabetes Registry. Diabetes Res Clin Practice. 2008;82:346-52.
17. UK Prospective Diabetes Study. UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS) 34. Lancet. 1998;352:852-65.
18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
19. García-Pérez LE, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Ther. 2013;4:175-94.
20. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization. Am J Manag Care. 2008;14:15-23.
21. Fox CS, Sullivan L, D’Agostino RB, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: The Framingham Heart Study. Diabetes Care. 2004;27:704-8.